Old Web
English
Sign In
Acemap
>
authorDetail
>
Robert N. Palmer
Robert N. Palmer
Takeda Pharmaceutical Company
Internal medicine
Medicine
Febuxostat
Cardiology
Placebo
5
Papers
47
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The GAINS trial - Growth and Anabolism In Intensive care Survivors
2020
Matthew Anstey
Rashmi Rauniyar
Ethan Fitzclarence
Ngan Tran
Emma Osnain
Bianca Mammana
Angela Jacques
Robert N. Palmer
Andrew R. Chapman
Bradley Wibrow
Show All
Source
Cite
Save
Citations (1)
Vitamin C and corticosteroids in viral pneumonia: a prospective cohort study
2020
Matthew Anstey
Jacky Lu
Erina Myers
Robert N. Palmer
Bradley Wibrow
Kwok M. Ho
Show All
Source
Cite
Save
Citations (0)
The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial
2018
American Heart Journal
Allison Hays
Micaela Iantorno
Michael Schär
Shenghan Lai
Matthew J. Czarny
Elayne Breton
Robert N. Palmer
Andrew Whelton
Robert G. Weiss
Gary Gerstenblith
Show All
Source
Cite
Save
Citations (8)
Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled Study
2017
Journal of the American Heart Association
Lhanoo Gunawardhana
Lachy McLean
Henry A. Punzi
Barbara Hunt
Robert N. Palmer
Andrew Whelton
Daniel I. Feig
Show All
Source
Cite
Save
Citations (30)
The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate
2012
British Journal of Clinical Pharmacology
Himanshu Naik
Jingtao Wu
Robert N. Palmer
Lachy McLean
Show All
Source
Cite
Save
Citations (8)
1